Cargando…
Cytoplasmic FOXO1 identifies a novel disease-activity associated B cell phenotype in SLE
Systemic lupus erythematosus (SLE) is a manifestation of hyperactivated lymphocytes and results, in part, from the loss of normal tolerance checkpoints. FOXO1 is a transcription factor involved at critical early and late B cell development checkpoints; however, its role in regulating peripheral B ce...
Autores principales: | Hritzo Ahye, Molly K, Golding, Amit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203050/ https://www.ncbi.nlm.nih.gov/pubmed/30397498 http://dx.doi.org/10.1136/lupus-2018-000296 |
Ejemplares similares
-
Cell-bound complement activation products associate with lupus severity in SLE
por: Arriens, Cristina, et al.
Publicado: (2020) -
Immune complex–driven neutrophil activation and BAFF release: a link to B cell responses in SLE
por: Wang, Ting, et al.
Publicado: (2022) -
Predictors of peripheral arterial disease in SLE change with patient’s age
por: Erdozain, Jose-Gabriel, et al.
Publicado: (2017) -
SARS-CoV-2 vaccines in patients with SLE
por: Tang, Wei, et al.
Publicado: (2021) -
LLDAS is an attainable treat-to-target goal in childhood-onset SLE
por: Wahadat, Mohamed Javad, et al.
Publicado: (2021)